Volume 4.40 | Oct 18

Prostate Cell News 4.40 October 18, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
HAI-2 Suppresses the Invasive Growth and Metastasis of Prostate Cancer through Regulation of Matriptase
Scientists delineated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) in prostate cancer (PCa) cell migration, invasion, tumorigenicity and metastasis using a human PCa progression model and xenograft models. [Oncogene] Abstract
[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Metformin Targets c-MYC Oncogene to Prevent Prostate Cancer
Scientists investigated the effect of metformin on c-myc expression and prostate cancer progression. Their results demonstrated that metformin reduced c-myc protein levels in vivo and in vitro. [Carcinogenesis] Abstract

Rottlerin Induces Autophagy and Apoptosis in Prostate Cancer Stem Cells via PI3K/Akt/mTOR Signaling Pathway
Scientists examined the molecular mechanisms by which rottlerin (Rott) induces autophagy in prostate cancer stem cells (CSCs). Rott-treated prostate CSCs induced transition from light chain-3 (LC3)-I to LC3-II, a hall mark of autophagy. [Cancer Lett] Abstract

The Interplay of AMP-Activated Protein Kinase and Androgen Receptor in Prostate Cancer Cells
Researchers showed that activation of AMP-activated protein kinase (AMPK) by metformin caused decrease of androgen receptor (AR) protein level through suppression of AR mRNA expression and promotion of AR protein degradation, demonstrating that AMPK activation is upstream of AR downregulation. [J Cell Physiol] Abstract

Impact of S100A8/A9 Expression on Prostate Cancer Progression In Vitro and In Vivo
Scientists established a prostate cancer epithelial cell line expressing S100A8 and S100A9 simultaneously under doxycycline control, to study the role of S100A8/A9 on tumor growth and infiltration of immune cells in subcutaneous xenografts in male NMRI nu/nu mice. [J Cell Physiol] Abstract

Differential Response of DU145 and PC3 Prostate Cancer Cells to Ionizing Radiation: Role of Reactive Oxygen Species, GSH and Nrf2, in Radiosensitivity
In the present study, the role of cellular redox and redox sensitive transcription factor, Nrf2 in the radiosensitivity of prostate cancer cell lines PC3 and DU145, was investigated. [Biochim Biophys Acta] Abstract

Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition
Researchers studied targeted therapy against Slug using combination of three drugs targeting three pathways respectively converging via Slug and further regulating prostate cancer (PCa) metastasis. Using in vitro assays they confirmed that Slug up-regulation incurred inhibition of E-cadherin that was anti-metastatic, and inhibited Bim-regulated cell apoptosis in PCa. [PLoS One] Full Article

A Novel Antitumor Piperazine Alkyl Compound Causes Apoptosis by Inducing RhoB Expression via ROS-Mediated c-Abl/p38 MAPK Signaling
Researchers investigated the action mechanism of a novel anticancer compound, KR28 (1-allyl-4-dodecanoyl-1-ethyl-piperazin-1-ium; bromide), to induce apoptosis of human prostate carcinoma PC-3 cells. The growth inhibitory action of KR28 is cell line specific, impeding the growth of prostate carcinoma PC-3 and stomach carcinoma NUGC-3 cells. [Cancer Chemother Pharmacol] Abstract

Human Kallikrein 2 (KLK2) Promotes Prostate Cancer Cell Growth via Function as a Modulator to Promote the ARA70-Enhanced Androgen Receptor Transactivation
Adding functional KLK2 cDNA into high passage LNCaP cells led to increased cell growth, and knockdown of KLK2 expression with KLK2-siRNA in LNCaP cells resulted in increased cell apoptosis with cell growth arrest at the G1 phase. [Tumor Biol] Abstract

CLINICAL RESEARCH

Translating Clinical Trials to Clinical Practice: Outcomes of Men with Metastatic Castration Resistant Prostate Cancer Treated with Docetaxel and Prednisone In and Out of Clinical Trials
Investigators compared outcomes of men with metastatic castrate-resistant prostate cancer (mCRPC) treated with docetaxel and prednisone in routine practice and in clinical trials. Survival of patients with mCRPC treated with docetaxel in routine practice is shorter than for men included in trials and is associated with more toxicity. [Ann Oncol] Abstract

Elevated Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) in Men with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy (ADT) Is Associated with Shorter Time to Castration Resistance and Overall Survival
Insulin-like growth factor and adipokines have been implicated in prostate cancer carcinogenesis. Data from 122 men with serum samples drawn within three months of starting ADT for metastatic prostate cancer was accessed retrospectively. [Prostate] Abstract

New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
 
REVIEWS
Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
Enzalutamide is an androgen receptor inhibitor that is indicated for the treatment of metastatic, castration-resistant, prostate cancer that has progressed despite treatment with docetaxel. The author reviews the pharmacology, efficacy and tolerability of enzalutamide relevant to this indication. [Drugs] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
The Terry Fox Foundation Tackles “Unmet Cancer Needs” with $13.6 Million for Rare Tumor, Lymphoma and Early-Stage Prostate and Esophogeal Cancer Research
Three exemplary Canadian cancer research teams are receiving $13.6 million from the Terry Fox Foundation to conduct cutting-edge research in several areas where there are unmet cancer needs. [The Terry Fox Foundation] Press Release

New Treatment Offers Hope to Advanced Prostate Cancer Patients
Men who have been diagnosed with advanced prostate cancer now have a new treatment option at Ocean Medical Center. Recently approved by the FDA, Xofigo is an intravenous injection of a radioactive material that treats metastatic prostate cancer resistant to medical or surgical treatments. [Meridian Health System, Inc.] Press Release

New wallchart from our sponsor: Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Keystone Symposia: Stem Cells and Cancer
February 2-7, 2014
Banff, Canada

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW PhD Student – Experimental Urology / Human Genetics (Radboud University Nijmegen Medical Centre)

Postdoctoral Fellow – Mechanisms of DNA Damage in the Development and Progression of Prostate Cancer (Johns Hopkins Hospital)

Senior Postdoctoral Researcher – Signaling and Metabolic Alterations in Prostate and Breast Cancer (CIC bioGUNE)

Research Technician Position – Steroid Receptor Signaling (Baylor College of Medicine)

Postdoctoral Research Associates – Tumor Immune Evasion Mechanism and Inflammation (Hollings Cancer Center)

Postdoctoral Fellow – Prostate Cancer and Head & Neck Cancer (University of Maryland Baltimore)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Prostate Cell News: Archives | Events | Contact Us